These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Werner MT; Zhao C; Zhang Q; Wasik MA Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258 [TBL] [Abstract][Full Text] [Related]
5. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340 [TBL] [Abstract][Full Text] [Related]
6. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198 [TBL] [Abstract][Full Text] [Related]
8. Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Kasprzycka M; Marzec M; Liu X; Zhang Q; Wasik MA Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9964-9. PubMed ID: 16766651 [TBL] [Abstract][Full Text] [Related]
9. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699 [TBL] [Abstract][Full Text] [Related]
10. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525 [TBL] [Abstract][Full Text] [Related]
11. Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogramming. Marzec M; Halasa K; Liu X; Wang HY; Cheng M; Baldwin D; Tobias JW; Schuster SJ; Woetmann A; Zhang Q; Turner SD; Ødum N; Wasik MA J Immunol; 2013 Dec; 191(12):6200-7. PubMed ID: 24218456 [TBL] [Abstract][Full Text] [Related]
12. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Chiarle R; Gong JZ; Guasparri I; Pesci A; Cai J; Liu J; Simmons WJ; Dhall G; Howes J; Piva R; Inghirami G Blood; 2003 Mar; 101(5):1919-27. PubMed ID: 12424201 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3. Marzec M; Kasprzycka M; Ptasznik A; Wlodarski P; Zhang Q; Odum N; Wasik MA Lab Invest; 2005 Dec; 85(12):1544-54. PubMed ID: 16170336 [TBL] [Abstract][Full Text] [Related]
15. IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK. Zhang Q; Wang HY; Liu X; Bhutani G; Kantekure K; Wasik M Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11977-82. PubMed ID: 21715655 [TBL] [Abstract][Full Text] [Related]
16. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma. Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060 [TBL] [Abstract][Full Text] [Related]
17. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Shi B; Vishwamitra D; Granda JG; Whitton T; Shi P; Amin HM Neoplasia; 2013 Jun; 15(6):669-83. PubMed ID: 23730215 [TBL] [Abstract][Full Text] [Related]
18. The heat shock protein-90 co-chaperone, Cyclophilin 40, promotes ALK-positive, anaplastic large cell lymphoma viability and its expression is regulated by the NPM-ALK oncoprotein. Pearson JD; Mohammed Z; Bacani JT; Lai R; Ingham RJ BMC Cancer; 2012 Jun; 12():229. PubMed ID: 22681779 [TBL] [Abstract][Full Text] [Related]
19. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
20. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]